2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1636

Decrease of Tocilizumab in Rheumatoid Arthritis in Remission : A Multicenter Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1089

Decreased B Cell Activation-Induced Apoptosis in Cells Overexpressing Interferon Regulatory Factor 5 (IRF5), a Gene Associated with Risk for Systemic Lupus Erythematosus and Other Autoimmune Diseases

B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's

9:00AM-11:00AM: Abstract Number: 1852

Decreased Expression of Sirtuin 7 By Lung Fibroblasts from Patients with Scleroderma Contributes to Elevated Collagen Production

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster II

9:00AM-11:00AM: Abstract Number: 1820

Dectin-1 on Monocytic Cells Mediates Aberrant Innate and Adaptive Immune Responses in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1653

Delineating the Effects of Rheumatoid Arthritis Pharmacotherapies on Vascular Inflammation: Rationale and Design of a Clinical Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - ARHP Poster

9:00AM-11:00AM: Abstract Number: 1821

Demethylated CD4+CD28+KIR+CD11ahi T Cells Are Characterized By a Pro-Inflammatory Transcriptome and Interact with Genetic Risk to Predict Disease Activity in Lupus

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1755

Dendritic Cell-Specific Loss of Caspase 8 Incites Symptoms of Neuropsychiatric Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 1441

Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Knockout Attenuates Arthritis Progression and Systemic Inflammation in TNF-Tg Arthritis Mouse Models

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1535

Depression in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1771

Depression Is Associated with a Poorer with Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1269

Description of Radiographic Hip Measurements By OA Status in a Large Community-Based Study of African American and White Men and Women

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1207

Design of a Multiplex Serum Proteome Assay to Monitor Biologic Drug Response in Rheumatoid Arthritis Patients

Genetics, Genomics and Proteomics - Poster II

9:00AM-11:00AM: Abstract Number: 1902

Detecting the Pulmonary Vascular Involvement and the Changes in Gene Activation Profiles at Early Stage of Systemic Sclerosis in Patients with Raynaud Phenomenon

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1480

Determination of the Lipid Profile in Active Disease Leads to Incorrect Cardiovascular Risk Prediction in Early Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1903

Determining Disease Course in Localized Scleroderma: A Prospective Cohort Study

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].